These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial. Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621 [TBL] [Abstract][Full Text] [Related]
5. The impact of colchicine on patients with acute and chronic coronary artery disease. Madanchi M; Young M; Tersalvi G; Maria Cioffi G; Attinger-Toller A; Cuculi F; Kurmann R; Bossard M Eur J Intern Med; 2024 Jul; 125():1-9. PubMed ID: 38238134 [TBL] [Abstract][Full Text] [Related]
6. The Role of Colchicine in Coronary Artery Disease. Butt AK; Cave B; Maturana M; Towers WF; Khouzam RN Curr Probl Cardiol; 2021 Mar; 46(3):100690. PubMed ID: 32994053 [TBL] [Abstract][Full Text] [Related]
7. Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials. Chen Y; Zhang H; Chen Y; Li M; Luo W; Liu Y; Fu Y; Xia H; Xu C; Jiang Y; Wu Y Clin Rheumatol; 2022 Jun; 41(6):1873-1887. PubMed ID: 35138464 [TBL] [Abstract][Full Text] [Related]
8. Colchicine for the treatment of coronary artery disease. Aimo A; Pascual-Figal DA; Barison A; Cediel G; Vicente ÁH; Saccaro LF; Emdin M; Bayes-Genis A Trends Cardiovasc Med; 2021 Nov; 31(8):497-504. PubMed ID: 33096241 [TBL] [Abstract][Full Text] [Related]
9. Colchicine in the Management of Acute and Chronic Coronary Artery Disease. Bouabdallaoui N; Tardif JC Curr Cardiol Rep; 2021 Jul; 23(9):120. PubMed ID: 34269908 [TBL] [Abstract][Full Text] [Related]
13. Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Kofler T; Kurmann R; Lehnick D; Cioffi GM; Chandran S; Attinger-Toller A; Toggweiler S; Kobza R; Moccetti F; Cuculi F; Jolly SS; Bossard M J Am Heart Assoc; 2021 Aug; 10(16):e021198. PubMed ID: 34369166 [TBL] [Abstract][Full Text] [Related]
14. The Role of Colchicine in Acute Coronary Syndromes. Vaidya K; Martínez G; Patel S Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. Bytyçi I; Bajraktari G; Penson PE; Henein MY; Banach M; ; Br J Clin Pharmacol; 2022 Feb; 88(4):1520-1528. PubMed ID: 34409634 [TBL] [Abstract][Full Text] [Related]
16. A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease. Chen T; Liu G; Yu B Clin Res Cardiol; 2023 Nov; 112(11):1487-1505. PubMed ID: 37505274 [TBL] [Abstract][Full Text] [Related]
17. API expert consensus document on management of ischemic heart disease. Association of Physicians of India J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697 [TBL] [Abstract][Full Text] [Related]
18. The Role of Colchicine in Atherosclerotic Cardiovascular Disease. Kurup R; Galougahi KK; Figtree G; Misra A; Patel S Heart Lung Circ; 2021 Jun; 30(6):795-806. PubMed ID: 33461916 [TBL] [Abstract][Full Text] [Related]
19. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]